| Schedule of Segment Reporting Information, by Segment |
| | | | | | | | | | | | | | | Biopharmaceuticals | | Bioprocessing | | | | | Year Ended June 30, 2022 (in thousands) | | iBio, Inc. | | iBio CDMO | | Eliminations | | Total | | | | | | | | | | | | | | Revenues - external customers | | $ | 1,884 | | $ | 499 | | $ | — | | $ | 2,383 | Revenues - intersegment | | | 1,586 | | | 2,455 | | | (4,041) | | | — | Cost of goods sold | | | — | | | 216 | | | — | | | 216 | Gross profit | | | 3,470 | | | 2,739 | | | (4,041) | | | 2,167 | Research and development | | | 11,819 | | | 8,260 | | | (2,350) | | | 17,729 | General and administrative | | | 20,844 | | | 14,975 | | | (1,691) | | | 34,128 | Operating loss | | | (29,194) | | | (20,496) | | | — | | | (49,690) | Interest expense | | | — | | | (1,412) | | | — | | | (1,412) | Forgiveness of note payable and accrued interest | | | — | | | 607 | | | — | | | 607 | Interest and other income | | | 184 | | | 7 | | | — | | | 191 | Consolidated net loss | | | (29,010) | | | (21,295) | | | — | | | (50,305) | Total assets | | | 156,893 | | | 43,092 | | | (100,578) | | | 99,407 | Finance lease ROU assets | | | — | | | 74 | | | — | | | 74 | Operating lease ROU assets | | | 3,068 | | | 1,952 | | | — | | | 5,020 | Fixed assets, net of accumulated depreciation | | | 1,373 | | | 35,288 | | | — | | | 36,661 | Intangible assets, net of accumulated amortization | | | 4,851 | | | — | | | — | | | 4,851 | Amortization of ROU assets | | | — | | | 599 | | | — | | | 599 | Depreciation expense | | | — | | | 2,275 | | | — | | | 2,275 | Amortization of intangible assets | | | 401 | | | — | | | — | | | 401 |
| | | | | | | | | | | | | | | Biopharmaceuticals | | Bioprocessing | | | | | Year Ended June 30, 2021 (in thousands) | | iBio, Inc. | | iBio CDMO | | Eliminations | | Total | | | | | | | | | | | | | | Revenues - external customers | | $ | 1,098 | | $ | 1,274 | | $ | — | | $ | 2,371 | Revenues - intersegment | | | 1,017 | | | 1,307 | | | (2,324) | | | — | Cost of goods sold | | | 425 | | | 1,037 | | | — | | | 1,462 | Gross profit | | | 1,690 | | | 1,543 | | | (2,324) | | | 909 | Research and development | | | 2,960 | | | 8,370 | | | (1,341) | | | 9,989 | General and administrative | | | 13,429 | | | 9,585 | | | (983) | | | 22,031 | Operating loss | | | (14,699) | | | (16,412) | | | — | | | (31,111) | Interest expense | | | — | | | (2,454) | | | — | | | (2,454) | Settlement income | | | 10,200 | | | — | | | — | | | 10,200 | Interest and royalty income | | | 151 | | | 1 | | | — | | | 152 | Consolidated net loss | | | (4,349) | | | (18,864) | | | — | | | (23,213) | Total assets | | | 175,272 | | | 35,721 | | | (64,025) | | | 146,968 | Finance lease ROU assets | | | — | | | 26,111 | | | — | | | 26,111 | Fixed assets, net of accumulated depreciation | | | — | | | 8,628 | | | — | | | 8,628 | Intangible assets, net of accumulated amortization | | | 952 | | | — | | | — | | | 952 | Amortization of finance lease ROU assets | | | — | | | 1,651 | | | — | | | 1,651 | Depreciation expense | | | — | | | 472 | | | — | | | 472 | Amortization of intangible assets | | | 291 | | | — | | | — | | | 291 |
|